Total Payments
$24,729
2024 Payments
$3,080
Companies
50
Transactions
1,433
Medicare Patients
1,439
Medicare Billing
$513,953
Payment Breakdown by Category
Food & Beverage$22,132 (89.5%)
Consulting$2,400 (9.7%)
Education$196.49 (0.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $22,132 | 1,427 | 89.5% |
| Consulting Fee | $2,400 | 1 | 9.7% |
| Education | $196.49 | 5 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB, Inc. | $4,712 | 180 | $0 (2024) |
| ABBVIE INC. | $3,107 | 178 | $0 (2024) |
| Amgen Inc. | $2,958 | 175 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,078 | 147 | $0 (2024) |
| Janssen Biotech, Inc. | $1,515 | 92 | $0 (2024) |
| PFIZER INC. | $1,213 | 79 | $0 (2024) |
| Horizon Therapeutics plc | $990.45 | 79 | $0 (2023) |
| GlaxoSmithKline, LLC. | $895.27 | 53 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $866.34 | 41 | $0 (2024) |
| Lilly USA, LLC | $785.73 | 49 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,080 | 171 | ABBVIE INC. ($711.89) |
| 2023 | $2,875 | 163 | AbbVie Inc. ($687.78) |
| 2022 | $2,808 | 193 | UCB, Inc. ($534.17) |
| 2021 | $2,704 | 186 | Amgen Inc. ($529.94) |
| 2020 | $1,612 | 104 | Amgen Inc. ($233.32) |
| 2019 | $2,887 | 193 | Novartis Pharmaceuticals Corporation ($336.73) |
| 2018 | $5,887 | 226 | UCB, Inc. ($2,597) |
| 2017 | $2,875 | 197 | Novartis Pharmaceuticals Corporation ($297.79) |
All Payment Transactions
1,433 individual payment records from CMS Open Payments — Page 1 of 58
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $36.49 | General |
| Category: Immunology | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $33.29 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $1.34 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/06/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Immunology | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $38.24 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $1.51 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/15/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/14/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Organon Llc | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: INFLIXIMAB | ||||||
| 11/04/2024 | Organon Llc | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $1.27 | General |
| Category: INFLIXIMAB | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $30.09 | General |
| Category: Dermatology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $4.05 | General |
| Category: Immunology | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 377 | 941 | $184,461 | $56,228 |
| 2022 | 9 | 357 | 5,886 | $592,577 | $113,028 |
| 2021 | 10 | 347 | 6,942 | $686,125 | $136,497 |
| 2020 | 7 | 358 | 41,044 | $792,570 | $208,200 |
Total Patients
1,439
Total Services
54,813
Medicare Billing
$513,953
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 200 | 377 | $67,860 | $29,392 | 43.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 69 | $18,630 | $8,699 | 46.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 39 | 39 | $15,678 | $5,692 | 36.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 15 | 57 | $34,200 | $4,645 | 13.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 15 | 78 | $16,380 | $3,504 | 21.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 189 | $14,553 | $1,967 | 13.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 66 | $9,900 | $1,342 | 13.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 31 | 66 | $7,260 | $988.84 | 13.6% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 13 | 5,100 | $430,950 | $60,683 | 14.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 188 | 378 | $68,040 | $30,027 | 44.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 35 | 53 | $14,310 | $6,650 | 46.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 17 | 59 | $35,400 | $5,630 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 28 | 28 | $11,256 | $3,998 | 35.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 25 | 72 | $15,120 | $3,502 | 23.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 12 | 117 | $9,009 | $1,244 | 13.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 28 | 57 | $6,270 | $832.16 | 13.3% |
| 73120 | X-ray of hand, 2 views | Office | 2022 | 11 | 22 | $2,222 | $460.78 | 20.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2021 | 13 | 6,100 | $515,450 | $83,696 | 16.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 182 | 379 | $68,220 | $31,344 | 45.9% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 23 | 89 | $53,400 | $9,170 | 17.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 31 | 48 | $12,960 | $5,808 | 44.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 21 | 46 | $9,660 | $2,413 | 25.0% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 12 | 58 | $8,700 | $1,318 | 15.1% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 29 | 61 | $6,710 | $1,025 | 15.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 14 | 93 | $7,161 | $988.59 | 13.8% |
About Dr. Bridget Wright, MD
Dr. Bridget Wright, MD is a Rheumatology healthcare provider based in Macon, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861506768.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bridget Wright, MD has received a total of $24,729 in payments from pharmaceutical and medical device companies, with $3,080 received in 2024. These payments were reported across 1,433 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($22,132).
As a Medicare-enrolled provider, Wright has provided services to 1,439 Medicare beneficiaries, totaling 54,813 services with total Medicare billing of $513,953. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Macon, GA
- Active Since 08/18/2006
- Last Updated 01/27/2016
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1861506768
Products in Payments
- Cimzia (Drug) $2,162
- RINVOQ (Biological) $1,729
- Enbrel (Biological) $1,696
- COSENTYX (Biological) $1,578
- XELJANZ (Drug) $1,015
- KRYSTEXXA (Biological) $983.45
- BENLYSTA (Biological) $895.27
- LUPKYNIS (Drug) $866.34
- Humira (Biological) $570.28
- TREMFYA (Drug) $541.03
- TALTZ (Drug) $508.90
- COSENTYX (Drug) $500.59
- KEVZARA (Drug) $490.96
- ACTHAR (Biological) $486.56
- SIMPONI ARIA (Biological) $479.95
- SKYRIZI (Biological) $419.96
- REMICADE (Biological) $398.30
- ORENCIA (Biological) $396.91
- RAYOS (Drug) $395.27
- Rituxan (Biological) $382.44
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.